Apollo Endosurgery, Inc.
7000 Bee Caves Road
149 articles with Apollo Endosurgery, Inc.
Apollo Endosurgery Announces Publication of Outcomes of Endoscopic Sleeve Gastroplasty (ESG) in 1,000 Consecutive Patients
Apollo Endosurgery, Inc. announced the publication of Outcomes of Endoscopic Gastroplasty in 1,000 Consecutive Patients from a single center - King Saud University, Riyadh, Saudi Arabia featured in Gastrointestinal Endoscopy
Apollo Endosurgery, Inc., today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc.
Apollo Endosurgery Announces First Commercial Shipment of the OverStitch™ Sx Endoscopic Suturing System
Apollo Endosurgery, Inc. announced today the first commercial shipments of the OverStitch™ Sx Endoscopic Suturing System. These initial customer shipments launch the first phase of the global product launch for Overstitch Sx.
Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Obesity Week 2018 Conference
Apollo Endosurgery, Inc. today announced its participation during Obesity Week 2018 taking place November 11-15, 2018 at The Music City Center in Nashville, Tennessee.
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET
Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2018 on Thursday, November 8, 2018,
Apollo Endosurgery Announces Distribution Agreement with Slater Endoscopy for the Ensizor® Flexible Endoscopic Scissors
Apollo Endosurgery, Inc. announced today that it has entered into an agreement with Slater Endoscopy, LLC to distribute the cold Ensizor® Flexible Endoscopic Scissors.
Apollo Endosurgery, Inc. today announced completion of enrollment in the ORBERA® Post Approval Study evaluating the ORBERA intragastric balloon.
Apollo Endosurgery and Istituto Clinico Humanitas in Milano, Italy Establish European Registry for Flexible Endoscopic Suturing Procedures in Gastrointestinal Applications
Professor Alessandro Repici, Director of the Digestive Endoscopy Unit of Istituto Clinico Humanitas, will serve as the Principal Investigator.
OverStitch™ Product Sales Increase 37% Year-Over-Year
All of the common stock is being offered by Apollo.
Apollo Endosurgery, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Apollo Endosurgery Announces Presentation of Mayo Clinic’s Clinical Study of ORBERA® Intragastric Balloon in Patients with Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week® 2018 (DDW)
Apollo Endosurgery, Inc. announced today’s presentation of results from Mayo Clinic’s prospective open-label study of the ORBERA® Intragastric Balloon in patients with Nonalcoholic Steatohepatitis (“NASH”) at Digestive Disease Week 2018.
Apollo Endosurgery Announces Presentation of Intragastric Balloon Comparison Study at Digestive Disease Week® 2018 titled: “Fluid-Filled Intragastric Balloons are Superior to Gas-Filled Balloon”
Apollo Endosurgery, Inc. announced Digestive Disease Week presentation of a meta analysis that concluded fluid-filled balloons.
Apollo Endosurgery Announces Presentation of Mortality and Inpatient Costs of Revisional Bariatric Surgery
Apollo Endosurgery, Inc. announced the presentation of the study results “Mortality and Inpatient Costs of Revisional Bariatric Surgery: A Nationwide Analysis” at Digestive and Disease Week.
Apollo Endosurgery Announces FDA Approval of Revised Labeling for the ORBERA® Intragastric Balloon System
Apollo Endosurgery, Inc. announced today that the United States Food and Drug Administration (FDA) has approved updates to the ORBERA® Intragastric Balloon System’s U.S. labeling including a new Physician Directions for Use (DFU), Physician Training, and Patient Directions for Use. Apollo, working directly with the Food and Drug Administration, has developed these updates as a means of communicating ORBERA’s most current safety information to both physicians and patients.
Apollo Endosurgery, Inc. announced that Dr. Julie Shimer, who led Welch Allyn Inc. and Vocera Communications as its Chief Executive Officer and President, has been appointed to Apollo’s Board of Directors.
Apollo Endosurgery, Inc. announced today the enrollment of the first patient in a multicenter, randomized, controlled, double-blind study of the efficacy and safety of Endoscopic Sleeve Gastroplasty (“ESG”) using Apollo’s OverStitch™ Endoscopic Suturing System, in patients with non-alcoholic steatohepatitis (“NASH”).
Apollo Endosurgery, Inc. announced financial results for the first quarter ended March 31, 2018.
Apollo Endosurgery, Inc. announced that it plans to release its financial results for the first quarter ended March 31, 2018 on Thursday, May 3, 2018, after the U.S. stock markets close.